Phase 2Completed
Therapy With an Oxytocin Adjunct for Major Depression (TOAD2015)
Combined Use of Intranasal Oxytocin and Interpersonal Psychotherapy for the Treatment of Major Depressive Disorder (MDD): A Randomized Controlled Trial
- Sponsor
- Concordia University, Montreal (Academic or other)
- Enrollment
- 24 enrolled
- Conditions
- Depressive Disorder
- Interventions
- Oxytocin nasal spray or placebo
- Ages
- adults
- Registry
- NCT02405715
Full record on ClinicalTrials.gov
From the registry
This study evaluates the addition of intranasal oxytocin to the treatment of Major Depression using interpersonal psychotherapy. Half of the participants will receive a placebo adjunct to interpersonal psychotherapy, and the other half will receive oxytocin.
Primary outcomes
- Diagnostic status: Major Depressive Episode Using The SCID-IV [Change Score]
- Depressive symptoms (clinician-rated) 9Hamilton Rating Scale for Depression (HRS-D)[Change Score]
- Depressive symptoms (clinician-rated) Inventory for Depressive Symptomology (IDS-C) [Change Score]
- Stress and social functioning (Global Axis of Functioning using the SCID-IV (GAF) [Change Score]
History
Last registry update
Primary completion
Registered
Started